World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT01451827
Date of registration: 11/10/2011
Prospective Registration: No
Primary sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Public title: 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) NOCTURNE
Scientific title: A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Immediate-release Formulations in Subjects With Autosomal Dominant Polycystic Kidney Disease
Date of first enrolment: October 2011
Target sample size: 178
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01451827
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Frank Czerwiec, M.D., Ph.D.
Address: 
Telephone:
Email:
Affiliation:  Otsuka Pharmaceutical Development & Commercialization, Inc.
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Age 18 to 50

2. Subjects with:

- BMI between 19 and 35 kg/m2

- diagnosis of ADPKD by modified Ravine criteria:

- family history: 3cysts/kidney if by sonography or 5 by CT or MRI

- Without family history: 10 cysts per kidney

- an eGFR > 45 mL/min/1.73 m2 by the CKD-EPI equation

3. Subjects not planning to become pregnant willing to comply with birth control
requirements.

4. Subjects must be in good health as determined by screening tests.

5. Subjects providing informed consent and able to comply with all trial requirements.

Exclusion Criteria:

1. Subjects using diuretics within 14 days prior to randomization, or the requirement for
intermittent or constant diuretic use for any reason

2. Subjects who had an eGFR < 45 mL/min/1.73 m2 calculated based on the most recent
historical creatinine during the last 12 months

3. Subjects with:

- incontinence, overactive bladder, or urinary retention (eg, BPH), meaning
subjects with symptoms of frequent nocturia, as determined by medical history or
urinary urgency should be carefully evaluated to exclude non-ADPKD GU issues
prior to entry.

- liver disease, liver function abnormalities, or serology other than that expected
for ADPKD with cystic liver disease at baseline

- a history of renal surgery or cyst drainage within 6 months of randomization

- blood pressure 150/95 mmHg or < 90/40 mmHg.

- heart rate outside the range of 40 to 90 bpm.

- advanced diabetes with a history of poor control, evidence of significant renal
disease renal cancer, single kidney, or recent renal surgery

- other significant medical history that may interfere with the study objectives

- significant abnormalities in serum sodium concentration (< 135 or > 145 mEq/L)

- a history of drug and/or alcohol abuse within 2 years prior to screening

- clinically significant allergic reactions to tolvaptan or chemically related
structures such as benzazepines (eg, benzazepril, conivaptan, fenoldopam
mesylate, or mirtazapine)

4. Subjects having taken an investigational drug within 30 days preceding randomization
on Day 0

5. Subjects taking medications or having concomitant illnesses likely to confound
endpoint assessments, including taking approved (ie, marketed) therapies for the
purpose of affecting PKD cysts such as tolvaptan, somatostatin agonists (ie,
octreotide, sandostatin), Rapamune (sirolimus), anti-sense RNA therapies, other
vasopressin antagonists (eg, OPC-31260 [mozavaptan] and Vaprisol® [conivaptan]) or
agonists (eg, desmopressin), and cyst reduction surgery

6. Subjects on antihypertensives that have not been on the same antihypertensive regimen
for at least 30 days prior to the first dose of IMP

7. Subjects having contraindications to, or interference with, MRI assessments

8. Subjects with a history of serious mental disorders that, in the opinion of the
investigator, would exclude the subject from participating in this trial

9. Subjects with previous exposure to tolvaptan



Age minimum: 18 Years
Age maximum: 50 Years
Gender: All
Health Condition(s) or Problem(s) studied
Autosomal Dominant Polycystic Kidney Disease
Intervention(s)
Drug: Tolvaptan MR
Drug: Placebo
Drug: Tolvaptan IR
Primary Outcome(s)
Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 [Time Frame: Baseline to Week 3]
Secondary Outcome(s)
Percent Change From Baseline in TKV at Week 8. [Time Frame: Baseline to Week 8]
Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) [Time Frame: Baseline to Week 8]
Secondary ID(s)
156-09-290
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 13/08/2018
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT01451827
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history